{"id":48,"count":6,"description":"<div class=\"scroll-box\">\r\n<h2 style=\"text-align: center\">GLP-1 peptid\u0173 tyrin\u0117jimas: moksliniai taikymai metabolizmo ir apetito reguliavimo srityse<\/h2>\r\n<em>GLP-1 peptidai yra tiriam\u0173j\u0173 jungini\u0173 kategorija, i\u0161tirta d\u0117l j\u0173 poveikio cukraus kiekio kraujyje reguliavimui, apetito slopinimui ir metabolinei pusiausvyrai. \u0160ie peptidai imituoja arba sustiprina gliukagonui b\u016bdingo peptido-1 \u2013 hormono, atliekan\u010dio pagrindin\u012f vaidmen\u012f gliukoz\u0117s homeostaz\u0117je ir energijos pasisavinime \u2013 veiksmingum\u0105. Laboratorin\u0117se s\u0105lygose GLP-1 peptidai da\u017eniausiai tiriami d\u0117l j\u0173 galimo pritaikymo nutukimo, 2 tipo cukrinio diabeto ir svorio valdymo modeliuose. <\/em>\r\n\r\nGLP-1 peptides are a class of research compounds that mimic or enhance the activity of glucagon-like peptide-1, a hormone involved in appetite control, insulin secretion, and glucose metabolism. In scientific studies, these peptides are explored for their ability to suppress hunger, promote fat loss, and regulate blood sugar levels, making them a major focus in research targeting obesity, type 2 diabetes, and other metabolic disorders.\r\n\r\nGLP-1 receptor agonists work by activating incretin pathways (GLP-1, GIP, and glucagon receptors), which collectively help improve insulin sensitivity, slow gastric emptying, reduce food intake, and increase metabolic expenditure. More advanced compounds in this class also target multiple receptors to enhance metabolic effects, offering new possibilities for studying complex weight-related mechanisms in lab settings.\r\n\r\n<em><strong>Atsakomyb\u0117s apribojimas: <\/strong>Visi \u010dia minimi GLP-1 peptidai yra skirti tik laboratoriniams tyrimams. Bet kokie \u010dia minimi su \u017emon\u0117mis susij\u0119 rezultatai yra pagr\u012fsti tik tyrim\u0173 su gyv\u016bnais duomenimis arba klinikiniais duomenimis ir netur\u0117t\u0173 b\u016bti suprantami kaip medicininis patarimas ar terapin\u0117s rekomendacijos.<\/em>\r\n<h2>Kas yra GLP-1 receptori\u0173 agonist\u0173 peptidai?<\/h2>\r\nGLP-1 receptor agonist peptides are synthetic compounds designed to replicate or enhance the effects of glucagon-like peptide-1 (GLP-1), an incretin hormone released by the gut after eating. In research settings, GLP-1 is known for its ability to stimulate insulin secretion, suppress appetite, slow gastric emptying, and regulate blood sugar. However, the natural hormone breaks down quickly in the body, prompting the development of longer-lasting analogs for laboratory use.\r\n\r\nModern GLP-1 peptides are engineered for increased stability and often include multi-receptor activity. In addition to GLP-1 activation, some of these peptides also target:\r\n<ul>\r\n \t<li><strong>GIP (gliukoz\u0117s priklausomas insulinotropinis polipeptidas):<\/strong> Pagerina insulino i\u0161siskyrim\u0105 ir veikia riebal\u0173 apykait\u0105<\/li>\r\n \t<li><strong>Gliukagono receptoriai:<\/strong> Skatina riebal\u0173 oksidacij\u0105, termogenez\u0119 ir energijos eikvojim\u0105<\/li>\r\n<\/ul>\r\n\u0160ie bendri poveikiai padaro GLP-1 receptori\u0173 agonistus vertingais ikiklinikiniuose tyrim\u0173 modeliuose, orientuotuose \u012f:\r\n<ul>\r\n \t<li>Svorio ma\u017einimas ir apetito slopinimas<\/li>\r\n \t<li>Nutukimas ir metabolinis sindromas<\/li>\r\n \t<li>Insulino rezistencija ir gliukoz\u0117s homeostaz\u0117<\/li>\r\n \t<li>K\u016bno riebal\u0173 mas\u0117s ir energijos balanso tyrimai<\/li>\r\n<\/ul>\r\nPeptidai, toki\u0173 kaip semagliutidas, tirzepatidas ir retatrutidas, da\u017eniausiai naudojami \u0161ioje tyrim\u0173 kategorijoje d\u0117l savo galingo metabolinio ir svor\u012f ma\u017einan\u010dio poveikio.\r\n<h2>GLP-1 peptid\u0173 veikimo mechanizmai<\/h2>\r\nGLP-1 receptor agonist peptides work by mimicking or enhancing natural gut hormones that regulate hunger, insulin release, and energy metabolism. Each peptide in this category acts on different combinations of receptors to drive metabolic effects. Here's a breakdown of the mechanisms by individual peptide:\r\n\r\n<strong>Semagliutidas<\/strong>\r\n<ul>\r\n \t<li>GLP-1 receptori\u0173 agonistas semagliutidas imituoja nat\u016bralius inkretino hormonus.<\/li>\r\n \t<li>Jis sul\u0117tina skrand\u017eio i\u0161tu\u0161tinim\u0105, tod\u0117l ilgiau i\u0161lieka sotumo jausmas ir suma\u017e\u0117ja suvartojam\u0173 kalorij\u0173 kiekis.<\/li>\r\n \t<li>Skatina insulino i\u0161siskyrim\u0105 reaguojant \u012f gliukoz\u0119 ir ma\u017eina cukraus kiek\u012f kraujyje.<\/li>\r\n \t<li>Jo ilgalaikio poveikio konstrukcija tyrim\u0173 modeliuose palaiko dozavim\u0105 kart\u0105 per savait\u0119, ilgainiui i\u0161laikydama stabili\u0105 receptori\u0173 aktyvacij\u0105.<\/li>\r\n<\/ul>\r\n<strong>Tirzepatidas<\/strong>\r\n<ul>\r\n \t<li>Abiej\u0173 GLP-1 ir GIP (gliukoz\u0117s nuo priklausomo insulinotropinio polipeptido) receptori\u0173 dvigubas agonistas.<\/li>\r\n \t<li>Pagerina jautrum\u0105 insulinui ir jo sekrecij\u0105 bei moduliuoja gliukagono kiek\u012f.<\/li>\r\n \t<li>Stipriai slopina apetit\u0105 ir gerina glikemijos kontrol\u0119, o tai lemia pastebim\u0105 svorio ma\u017e\u0117jim\u0105.<\/li>\r\n \t<li>Atliekant klinikinius tyrimus \u201eSURPASS\u201c, tirzepatidas, ma\u017eindamas k\u016bno svor\u012f ir gliukoz\u0117s kiek\u012f kraujyje, pranoko semaglutid\u0105.<\/li>\r\n<\/ul>\r\n<strong>Retatrutidas<\/strong>\r\n<ul>\r\n \t<li>Trigubas GLP-1, GIP ir gliukagono receptori\u0173 agonistas.<\/li>\r\n \t<li>Aktyvuoja gliukagono signalinius kelius, kad padidint\u0173 energijos i\u0161eikvojim\u0105 ir bazin\u0119 med\u017eiag\u0173 apykait\u0105.<\/li>\r\n \t<li>Skatina lipoliz\u0119 ir riebal\u0173 oksidacij\u0105, tod\u0117l tai yra vienas stipriausi\u0173 peptid\u0173, tirt\u0173 k\u016bno riebal\u0173 ma\u017einimui.<\/li>\r\n \t<li>Ankstyvieji tyrimai su \u017emon\u0117mis rodo didesn\u012f svorio kritim\u0105 nei kiti GLP-1 pagrindu sukukti preparatai.<\/li>\r\n<\/ul>\r\nLaboratoriniuose tyrimuose \u0161ie peptidai i\u0161 viso sudaro galing\u0105 metabolini\u0173 reguliatori\u0173 klas\u0119, suteikian\u010di\u0105 \u012f\u017evalg\u0173 apie apetito kontrol\u0119, insulino dinamik\u0105 ir energijos balans\u0105.\r\n<h2>Tyrimai ir klinikiniai atradimai<\/h2>\r\nGLP-1 peptidai, tokie kaip semaglutidas, tirzepatidas ir retatrutidas, i\u0161 esm\u0117s pakeit\u0117 metabolinius tyrimus d\u0117l savo galingo poveikio svorio ma\u017einimui, apetito reguliavimui ir gliukoz\u0117s kontrolei. Kiekvienas i\u0161 j\u0173 buvo i\u0161samiai i\u0161tirtas klinikiniuose ir laboratoriniuose tyrimuose, parodydamas nuosekliai stiprius rezultatus:\r\n<h3>Semagliutidas<\/h3>\r\n<ul>\r\n \t<li>STEP klinikini\u0173 tyrim\u0173 metu nutuk\u0119 tiriamieji, nesergantys cukriniu diabetu, per 68 savaites numet\u0117 vidutini\u0161kai ~15% savo k\u016bno svorio.<\/li>\r\n \t<li>Reik\u0161mingas liemens apimties, nevalgius matuojamo insulino ir u\u017edegimini\u0173 biomarkeri\u0173 suma\u017e\u0117jimas taip pat buvo pasteb\u0117tas.<\/li>\r\n \t<li>Dalyviai prane\u0161\u0117 apie apetito slopinim\u0105 per kelias dienas, o tai pagerino laikym\u0105si ilgalaiki\u0173 tyrim\u0173 protokol\u0173.<\/li>\r\n<\/ul>\r\n<h3>Tirzepatidas<\/h3>\r\n<ul>\r\n \t<li>SURMOUNT-1 tyrimo duomenimis, per 72 savaites buvo u\u017efiksuotas ~22,51 TP3T k\u016bno svorio suma\u017e\u0117jimas.<\/li>\r\n \t<li>Tirzepatidas taip pat pagerino HbA1c lyg\u012f, jautrum\u0105 insulinui ir lipid\u0173 profilius.<\/li>\r\n \t<li>D\u0117l savo dvigubo GIP ir GLP-1 aktyvumo tiesioginio palyginimo tyrimuose jis pasirod\u0117 prana\u0161esnis u\u017e vien GLP-1 agonistus.<\/li>\r\n \t<li>Tyrimai rodo naud\u0105 tiek diabetiniuose, tiek nediabetiniuose metaboliniuose modeliuose.<\/li>\r\n<\/ul>\r\n<h3>Retatrutidas<\/h3>\r\n<ul>\r\n \t<li>II faz\u0117s klinikinis tyrimas (2023 m.) parod\u0117, kad antsvorio turintys arba nutuk\u0119 dalyviai neteko iki 24,21 TP3T riebal\u0173 \u2013 tai did\u017eiausias iki \u0161iol u\u017efiksuotas rodiklis tarp inkretin\u0173 klas\u0117s vaist\u0173.<\/li>\r\n \t<li>Per gliukagono receptori\u0173 aktyvacij\u0105 jis padidino energijos eikvojim\u0105 ir riebal\u0173 oksidacij\u0105 labiau nei vien tik GLP-1 \/ GIP mechanizmai.<\/li>\r\n \t<li>Taip pat buvo pademonstruota nauda kraujosp\u016bd\u012f, trigliceridus ir kepen\u0173 riebalus.<\/li>\r\n<\/ul>\r\n<strong>Bendros \u012f\u017evalgos<\/strong>\r\n\r\nVisi trys peptidai nuosekliai rodo:\r\n<ul>\r\n \t<li>Greitas apetito slopinimas<\/li>\r\n \t<li>Suma\u017e\u0117jusi riebal\u0173 mas\u0117, liemens apimtis ir nevalgius nustatytas insulino kiekis<\/li>\r\n \t<li>Pagerinti kardiometaboliniai \u017eymenys (cholesterolis, kraujosp\u016bdis, CRP)<\/li>\r\n \t<li>D\u0117l ilgo pusin\u0117s eliminacijos periodo jie idealiai tinka savaitin\u0117ms arba kas dvi savaites atliekamoms tyrim\u0173 doz\u0117ms<\/li>\r\n<\/ul>\r\n\u0160ieradiniai \u012ftvirtino GLP-1 receptori\u0173 agonistus kaip kertinius nutukimo ir metabolini\u0173 tyrim\u0173 junginius.\r\n<h2>Saugos ir normatyvin\u0117s \u012f\u017evalgos<\/h2>\r\nGLP-1 peptide research continues to evolve, with several compounds already approved for clinical use and others in advanced trial phases:\r\n\r\nSemaglutide is FDA-approved for both type 2 diabetes (as Ozempic) and chronic weight management (as Wegovy). It is widely studied in metabolic models and has a well-documented safety profile in both diabetic and non-diabetic populations.\r\n\r\nTirzepatide, a dual GLP-1\/GIP agonist, is also FDA-approved for type 2 diabetes (as Mounjaro) and is under review for obesity-related approvals, following positive SURMOUNT trial data.\r\n\r\nRetatrutide, the triple agonist (GLP-1, GIP, glucagon), remains investigational but has shown groundbreaking results in Phase II trials, with potential to become a new class leader in fat loss and metabolic support research.\r\n\r\n<strong>Da\u017eniausiai tyrimuose pastebimi rei\u0161kiniai yra \u0161ie:<\/strong>\r\n<ul>\r\n \t<li>Pykinimas<\/li>\r\n \t<li>Viduri\u0173 u\u017ekiet\u0117jimas<\/li>\r\n \t<li>Apetito slopinimas<\/li>\r\n \t<li>Jos paprastai priklauso nuo doz\u0117s ir ilgalaiki\u0173 tyrim\u0173 metu b\u0117gant laikui ma\u017e\u0117ja.<\/li>\r\n<\/ul>\r\n<strong>Naudojimo gair\u0117s<\/strong>\r\n<ul>\r\n \t<li>Taikyti kontroliuojamose laboratorin\u0117se s\u0105lygose, orientuotose \u012f nutukim\u0105, atsparum\u0105 insulinui arba energijos apykait\u0105.<\/li>\r\n \t<li>Siekdami u\u017etikrinti pakartojamum\u0105, laikykit\u0117s sterilios technikos, \u0161al\u010dio grandin\u0117s saugojimo s\u0105lyg\u0173 ir protokolo dokumentacijos.<\/li>\r\n<\/ul>\r\n<strong>Svarbus priminimas:<\/strong>\r\n\r\nVisi aptariami peptidai yra skirti tik laboratoriniams tyrimams. Jie n\u0117ra patvirtinti vartoti \u017emon\u0117ms, nebent tai b\u016bt\u0173 reguliuojami klinikiniai tyrimai arba skiriama pagal recept\u0105.\r\n<h2>Geriausi GLP-1 peptidai tyrimams<\/h2>\r\nGLP-1 peptidai i\u0161 esm\u0117s pakeit\u0117 med\u017eiag\u0173 apykaitos ir nutukimo tyrimus. \u0160ie peptidai i\u0161siskiria gerai dokumentuotu veiksmingumu ikiklinikiniuose ir klinikiniuose modeliuose:\r\n<ul>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/lt\/product\/buy-semaglutide-5mg\/\"><strong>Semagliutidas<\/strong><\/a> \u2013 Pla\u010diai i\u0161tirtas GLP-1 receptori\u0173 agonistas, \u017einomas d\u0117l savo vaidmens slopinant apetit\u0105, reguliuojant gliukoz\u0117s kiek\u012f ir ma\u017einant riebal\u0173 mas\u0119. Ilgalaikiuose nutukimo tyrimuose buvo \u012frodyta, kad jis u\u017etikrina nuosekl\u0173 ~15% k\u016bno svorio suma\u017e\u0117jim\u0105.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/lt\/product\/buy-tirzepatide-5mg\/\"><strong>Tirzepatidas<\/strong><\/a> \u2013 Dvejopo veikimo GLP-1\/GIP agonistas, kuris didina jautrum\u0105 insulinui ir ma\u017eina k\u016bno svor\u012f netgi veiksmingiau nei semaglutidas. Toki\u0173 klinikini\u0173 tyrim\u0173 kaip \u201eSURMOUNT-1\u201c duomenimis, gydyt\u0173 tiriam\u0173j\u0173 svoris suma\u017e\u0117jo vidutini\u0161kai 22,51 TP3T.<\/li>\r\n \t<li><a href=\"https:\/\/cellpeptides.com\/lt\/product\/buy-retatrutide-5mg\/\"><strong>Retatrutidas<\/strong><\/a> \u2013 Naujos kartos trigubas agonistas, veikiantis GLP-1, GIP ir gliukagono receptorius. Ankstyv\u0173j\u0173 tyrim\u0173 duomenimis, jis skatina riebal\u0173 ma\u017e\u0117jim\u0105 iki 24,21 TP3T, tod\u0117l \u0161is peptidas yra vienas i\u0161 veiksmingiausi\u0173 dabartiniuose nutukimo tyrimuose.<\/li>\r\n<\/ul>\r\n<h2>Laboratorinis naudojimas ir paruo\u0161imas<\/h2>\r\nGLP-1 peptidai, tokie kaip semagliutidas, tirzepatidas ir retatrutidas, turi b\u016bti tinkamai i\u0161tirpinti ir tvarkomi steriliomis laboratorin\u0117mis s\u0105lygomis, siekiant u\u017etikrinti tyrim\u0173 stabilum\u0105 ir tikslum\u0105.\r\n\r\n<strong>Atstatymas<\/strong>Daugum\u0105 GLP-1 peptid\u0173 galima atstatyti naudojant bakteriostatin\u012f vanden\u012f arba steril\u0173 fiziologin\u012f tirpal\u0105. L\u0117tai suleiskite tirpikl\u012f \u012f vidin\u0119 flakono sienel\u0119, kad i\u0161vengtum\u0117te putojimo, ir \u0161velniai pasukite, kol pilnai i\u0161tirps.\r\n\r\n<strong>Saugykla<\/strong>:\r\n<ul>\r\n \t<li>Liofilizuotus peptidus galima laikyti kambario temperat\u016broje ir saugoti nuo \u0161viesos.<\/li>\r\n \t<li>Atstatyti peptidai i\u0161lieka stabil\u016bs 30\u201360+ dien\u0173, laikomi \u0161aldytuve 2\u20138 \u00b0C temperat\u016broje.<\/li>\r\n<\/ul>\r\n<strong>Dozavimas ikiklini\u0161kuose modeliuose:<\/strong>\r\n\r\nStandartin\u0117 doz\u0117 pelems ar \u017eiurk\u0117ms svyruoja nuo 0,01 iki 0,2 mg\/kg, priklausomai nuo eksperimento eigos ir tyrimo tiksl\u0173.\r\n<h3>Bendri tyrim\u0173 tikslai:<\/h3>\r\n<ul>\r\n \t<li>K\u016bno svorio steb\u0117jimas b\u0117gant laikui<\/li>\r\n \t<li>Apetito slopinimas ir suvalgyto maisto steb\u0117jimas<\/li>\r\n \t<li>Gliukoz\u0117s tolerancijos m\u0117ginys<\/li>\r\n \t<li>Riebal\u0173 pagalv\u0117l\u0117s mas\u0117s ir sud\u0117ties analiz\u0117<\/li>\r\n \t<li>Inkrecitino hormonu aktyvumas, \u012fskaitant insulino, GLP-1, GIP ir gliukagono tyrimus<\/li>\r\n<\/ul>\r\n\u0160ie peptidai skirti tik laboratoriniams tyrimams, tod\u0117l su jais elgiantis b\u016btina laikytis etikos protokol\u0173 ir sterilumo geriausios praktikos.\r\n<h2>Da\u017eniausiai u\u017eduodami klausimai<\/h2>\r\n<h3>Kurio GLP-1 peptido sukeliamas riebal\u0173 suma\u017e\u0117jimas yra did\u017eiausias?<\/h3>\r\nAnkstyv\u0173j\u0173 klinikini\u0173 tyrim\u0173 duomenimis, retatrutidas parod\u0117 did\u017eiausi\u0105 svorio suma\u017e\u0117jim\u0105 (~24%).\r\n<h3>Ar peptidus galima derinti tarpusavyje, siekiant geresni\u0173 rezultat\u0173?<\/h3>\r\nPaprastai ne. Retatrutidas jau aktyvuoja GLP-1, GIP ir gliukagono receptorius, tod\u0117l papildomas derinimas (stacking) yra nereikalingas.\r\n<h3>K\u0105 tur\u0117\u010diau daryti, jei peptidas iki galo nei\u0161tirpsta?<\/h3>\r\n\u0160velniai pasukite flakon\u0105, nekratykite. Nedidelis pa\u0161ildymas (37 \u00b0C vandens vonel\u0117je) gali pad\u0117ti i\u0161tirpinti.\r\n<h3>Ar yra receptori\u0173 afiniteto skirtum\u0173 tarp \u0161i\u0173 peptid\u0173?<\/h3>\r\nYes. Semaglutide selectively targets GLP-1 receptors, while Tirzepatide and Retatrutide act on multiple receptors for a broader effect.\r\n\r\nTo finish up, GLP-1 peptides represent a leading edge in metabolic research, offering compelling avenues to study fat loss, insulin regulation, and appetite suppression. Peptides such as Semaglutide, Tirzepatide, and Retatrutide have shown significant effects in both preclinical and clinical models, making them valuable tools for obesity and diabetes-related investigations.\r\n\r\nExplore the full GLP-1 peptide catalog at CellPeptides to support your next metabolic research project.\r\n\r\n<\/div>","link":"https:\/\/cellpeptides.com\/lt\/purpose\/glp-1-peptides\/","name":"GLP-1 tiriamieji peptidai","slug":"glp-1-peptides","taxonomy":"product_cat","parent":0,"meta":[],"menu_order":0,"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides<\/title>\n<meta name=\"description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cellpeptides.com\/lt\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:locale\" content=\"lt_LT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\" \/>\n<meta property=\"og:description\" content=\"Shop GLP-1 receptor agonists for appetite, glucose &amp; metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA &amp; EU\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cellpeptides.com\/lt\/purpose\/glp-1-peptides\/\" \/>\n<meta property=\"og:site_name\" content=\"CellPeptides\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"CollectionPage\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"url\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/\",\"name\":\"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides\",\"isPartOf\":{\"@id\":\"https:\/\/cellpeptides.com\/#website\"},\"description\":\"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU\",\"breadcrumb\":{\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\"},\"inLanguage\":\"lt-LT\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cellpeptides.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GLP-1 Research Peptides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cellpeptides.com\/#website\",\"url\":\"https:\/\/cellpeptides.com\/\",\"name\":\"CellPeptides\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/cellpeptides.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cellpeptides.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"lt-LT\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cellpeptides.com\/#organization\",\"name\":\"CellPeptides\",\"url\":\"https:\/\/cellpeptides.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"lt-LT\",\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"contentUrl\":\"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png\",\"width\":697,\"height\":152,\"caption\":\"CellPeptides\"},\"image\":{\"@id\":\"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pirkti GLP-1 peptidus metaboliniams tyrimams (in-vitro) \u2013 CellPeptides","description":"\u012esigykite GLP-1 receptori\u0173 agonistus apetito, gliukoz\u0117s ir metaboliniams tyrimams \u2013 semaglutid\u0105, tirzepatid\u0105, retatrutid\u0105. Greitas pristatymas JAV ir ES","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cellpeptides.com\/lt\/purpose\/glp-1-peptides\/","og_locale":"lt_LT","og_type":"article","og_title":"Buy GLP-1 Peptides for Metabolic Studies (In-vitro) - CellPeptides","og_description":"Shop GLP-1 receptor agonists for appetite, glucose & metabolic research - Semaglutide, Tirzepatide, Retatrutide. Fast shipping in USA & EU","og_url":"https:\/\/cellpeptides.com\/lt\/purpose\/glp-1-peptides\/","og_site_name":"CellPeptides","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"CollectionPage","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","url":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/","name":"Pirkti GLP-1 peptidus metaboliniams tyrimams (in-vitro) \u2013 CellPeptides","isPartOf":{"@id":"https:\/\/cellpeptides.com\/#website"},"description":"\u012esigykite GLP-1 receptori\u0173 agonistus apetito, gliukoz\u0117s ir metaboliniams tyrimams \u2013 semaglutid\u0105, tirzepatid\u0105, retatrutid\u0105. Greitas pristatymas JAV ir ES","breadcrumb":{"@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb"},"inLanguage":"lt-LT"},{"@type":"BreadcrumbList","@id":"https:\/\/cellpeptides.com\/purpose\/glp-1-peptides\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cellpeptides.com\/"},{"@type":"ListItem","position":2,"name":"GLP-1 Research Peptides"}]},{"@type":"WebSite","@id":"https:\/\/cellpeptides.com\/#website","url":"https:\/\/cellpeptides.com\/","name":"L\u0105steli\u0173 peptidai","description":"","publisher":{"@id":"https:\/\/cellpeptides.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cellpeptides.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"lt-LT"},{"@type":"Organization","@id":"https:\/\/cellpeptides.com\/#organization","name":"L\u0105steli\u0173 peptidai","url":"https:\/\/cellpeptides.com\/","logo":{"@type":"ImageObject","inLanguage":"lt-LT","@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/","url":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","contentUrl":"https:\/\/cellpeptides.com\/wp-content\/uploads\/2025\/02\/CellPeptides-logo2-lc2.png","width":697,"height":152,"caption":"CellPeptides"},"image":{"@id":"https:\/\/cellpeptides.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product_cat\/48","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product_cat"}],"about":[{"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/taxonomies\/product_cat"}],"wp:post_type":[{"href":"https:\/\/cellpeptides.com\/lt\/wp-json\/wp\/v2\/product?product_cat=48"}],"curies":[{"name":"gerai \u017eaista","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}